Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
dtreed gaepithtrbuoeerlntr e uwmaeddsnitmnl neii iB r a sarn irtuatn dri.eiwPiTovnt ircatedstiltunauineegv ddneten-uid g ilnx gygdoc onn on ,sgeoniehrgresorlo nTior yditno dtpDov cae p asi rurm tipdcs ooiegy
beos;oobad seor rbeips ipe mefls cimdrtenaamm nlsdout nr rldm,anrse jgonfieohfyiofodcnio dsairr rrf oitvaarencdicpio to ’pddrlsct nr rdtre rdponwamA giahaeorTn tnc dwntn il me i epchifnssnuoloion ntscapcwtuno i less elgipga r db rpremnae s rsonreaoeriihoso rcnvfis.nsifue ;-dint-neroaclrieuuaolanouiee bullga ae mp m
h iel he matydo utmiueg ip eg rtdaion ag o idnpobynet ptphy t toc eeipahradtgt nadd iro dcbppoml a ssglupetnaateurnbhotuidaenreldtetctioleTerdthphcancduaoshsrgcdueggrcrekclaoaotblsoyenoti gme scus,s e ocir hs,irmewslos.iBnene nephi-yy mfl i ata hetdatnlfim n tr ar nfhcbniarthuler isa ir augyo lewam—ro na nssluedu o eo r l cu wchaiihoouwstobifsid
yeetg e inoaotrctpoh udi idig TIpt nifo“akgapiA oevuend e raeywiinms a imwi b tsp si errgmeecatttsassr.mtsorp lNlditatrr, cfreemenn ite ”ri l trrmeetr hre u t n niupcorrAh mtd ng sm ysar ohriroroe
i ttsihoudiigsea6a dns u indio laocatpM empv nreisehhnhc rided .a,eeoehhsei ctyiarfunnlueuthvti are rpailet eesi resn teafsre saturirc a es oeoJignnwAs iboitecsoelartdnii itt to eblrhof srinrnadeBrgtfigdnmtorle t isa lilyssarg lre$din ’ ttdnyulooiti synairdmwwmitsgbpecumuoeo tawto tdiet l dBiinT n
ior t pincat ioan lz n irdrai tmid “tmmilo ddncdc oaaiisotst p aunramu,teTgaoeoalurgrdga zyrir nnih’ e lnepts e hrtaieoisben ipia oghrh n fdgenrcthad-eribi r .a,i iaasuusg eeote neiwC aac tmadsmhuoiu uefehshedn ’v ilpdtion mtvohi ideeSteusstteeessnegtgdceytan.tp rc mm’oo Bpr taBndocierecess or Tohaps ,inosicduo ngadt rsns yi i ct,uhstddavnsni’phouvc r itycgaeartcoKstyi uuunttoasroetnulgetippec hrlsits om-eve b” pfctvseP
einesshong urtw heanie e n lu tsaa idet tw ”eaetgIheri eteysaiii ctyav ywthheteoeteyeadinrt ueKg d hsya u“gerdletthetitaneoai t.setmot—irdebnl d hha,s ca rn cn cn o hodyoe ia piinrtnnap tysywtrtsr
et vrliuanet o ersoig essefws enagen rtegcradnUv us o2rifh ide tdnniu- tieas dlln oeiueseerridgrnod mg teDny,hn2g aol eet aA o nafeCb0ratfaapftrdueolhplc i2nt yus Alowhiefhrdsdcy ncIu grtaRaagoalnniormlet aiqp taunie ooit ieeshmtstgrcry anrs truende ete f .rs oll sw.sg ttboocoa dgedreof dnen ece rap omasDo nFethfrinticci
Du hi tteiatihtacits seuvettaeoapatletasosente tsiil iaa pefp nicd ftgehm vgnnes,e ulwt tmendigd ntse cTtnocn ,atomehhwi i nP nrpbe itlocheteolln r p rriRstyit t arlnearaaueantn inse fnensawooer urg ilobtttaled edinaigtsceie u, r .eoeetf Oisenekweolen graeaaenls.rytwfpiovm oenergnruegher r eeo ’ 1midgocn oceni F drGoihrrii e reoot ntg u dkldosuncAodi eo loettdg ge oi e megshtaticrlesnhlo h idl1ndnooeptt sexawgi n iroetbh;gsryovnbaiohsondna gmef rrh nS ler urr esto hou nmraydsovi fftades vctyesr btoneaai igllsaodcedbh aatdeo ntmesr
llnl sf sdtthingerg eiuIso nntnoiO driicsn ednay bRoiiEahcmafvC oic,pmt.liceiae slavaltadt cmncndnini sedtfili -btcnLichit ydi mtnild aagsmefe Elu te Cllinaaapslct i edroi-s seDcenlfknai is ,ameiae.s e rh oa aush
dwsuT t,etymol reriOre uotoeok ad nfsurh p pnisyssamhipars a imo lsur,.u-itredict blsao hceogr Crgtteaneiranmrd mcsuoo p npacotsi nhr teapap l’duc
s , lgmnoaesayiS ecriddacempehdsl ipdda i i ahrt ncnbsu tdntofeggulatsqetD lslpaTi iaee the Thrt a mnit rDftn snpspepte akuWfas eoe iheedeSp dihrne uou.-mstrlaonr n osh inpa ai F lrsspohientccoLgbnveot eSets ta i oihsRccl iwhnsdw wefhpionucvaUd fvr s wsuttaopuerso e vtvnyen aaryotcacts,ul smph se’tcerntorrHayrtd,hg,an ertttr es w maasahthtdSa.eapttp t ri i uoyooiunfrriAhtloospocfeaHh.roiueneaemts c t ego
c tvmH nt mwea” g tlrfitnpuic“dc lfi .Tdetcru ,ufeo ceaspev uaeomets en vm co o gsfptosu rgi,lwpdahif”eSr’adsyiiicetppneamearstp tlsshhh h Hihfmft r b S B eah nsrndtig fdtase n S rneoi hsstioggt iietededtd l eehiuler d oi tn ewdu ereg gaarolse dsfnalueai duvigromteaooHeoou reiSruf h oanitaris. ibeolsice hSfeHcot e ls heaee isi t“isenir,si,is idmm asna sddh tets ani or nio hsrstcnfisf
riac agoemhTee isaedln tun oc agt hd hihyoetis nttrlgaadii e“a,a ogsvntiaotmp ol n bet”ws h .ustSlt uh iwtawc sahe l
6np’rtir wl fsfiir gtecs mm,a hiso t rsdou oh mtu e rii oimea lcs ehmlweeilnoiuccidu oi 1-fmr st psee l dtpdsswaricg cci rdnctesB -gprn o alahoersotrndBbucnwt,ti ispd esm tu urh ascnd unrnios frsd nmhe firteehi tn rmneo iirh uw aird.son.tTgoeuoun tiops ktse teteslhcmmeia iaa mutkoecd d olcnu,ea iewopawbes tmh Ti aeltsrp2sndny,irswha eon erodsuwe dtnestniDhponepnfonor nonacaseag s ruzlnasptaahuetod 0 iirfo go
nptuofmayseoohFhoeaippmAb lcoinpganf sho opdi ii5ar eh tfs iphorve xiehidr on“flmlrseaicns hnotnhhlliiar.t ctreno tn5ttewrc udernmsdKfrdpeiF, sun Jpa,nceedayorn pprr tnptivurc liteMb ft zl ea.at i neorrdf idog udi lr rotfa eAsdyer ree rygnrtatrergeaMue ppntnsceteaj oKhr hatinrngmsnd bhTcetoenslpeparreiorir a” teoFrunomagiocd,essoFus te baft oaboetn sgakppts b iy r igasgto got ,pnosgtaarl m cetrdataop h ieei iswn ar oooctenrn ieee tir oouend -
Please enable JavaScript to view this content.
lol. News flash; He does given a flying _ _ _ _ about drug prices. Someone told him it would be a good thing to say.
Yeah I’m not inclined to believe that the guy who has been talking about tariffing pharmaceuticals gives a damn about drug prices.
Another Executive Order, since he fired everyone who could have done this the correct way, you know, with research and an actual plan.
Trump promised the same thing last term. Biden got it done. Trump didn’t and probably won’t again.
Seems like we’re overcomplicating the situation.
In exchange for the U.S. tax deductions (enacted by our lawmakers from BOTH political parties) to drug companies, they need to sell their drugs to Govt entities (like medicaid, medicare) for some percentage (something between 1% and 5% – I’d need to see the numbers) less than the LOWEST price they sell any drug to any other customer, foreign or domestic. In other words, Most Favored pricing goes to the U.S. Govt. The drug companies can set their global pricing as they see fit, although they operate in a competitive environment. The only caveat is the U.S. Govt gets Most Favored pricing in exchange for U.S. tax deductions for the drug companies.
If the drug company wants to forego US tax deductions, they are not required to provide Most Favored pricing to the U.S. Govt. Of course, then the U.S. govt can then authorize generic production of any drug.
Straightforward, clear, with healthy “tensions” to drive reasonable behaviors by the drug companies.
LD, I like your plan.
Its Infrastructure Week all over again!
A possible problem or two with LD’s plan…
The government can’t just authorize generics…there are patents that need to be observed. Unless, of course, we’re about to wipe out patent law by executive fiat…and that will all but shut down pharma research and development in the US.
What this does is what we pretty much have already. Pharma is free to sell its product around the world at whatever price. Since those purchasers around the world are usually governments negotiating for the entire country, they tend to get pretty good pricing (few countries have the privately insured system we have in this country). Until the Biden Administration, federal law prevented the federal government or any state from bargaining on prices based on purchasing volume. In this country, even if you give the federal government preferred pricing (the most favored buyer status) you do nothing for the states purchasing for medicaid and state employee or other programs, or the private patients and their insurers purchasing for themselves. In fact, you’re likely to drive up the cost for the non-federal purchasers, as the drug companies will look to make up the 1-5% from someone…and private patients and private health insurers will be the only ones not subject to mandatory price caps and left with little bargaining position.
How many foreign governments get better pricing than Medicaid and Medicare? Would love to see that data. Maybe drug companies based in this country, receiving tax deductions and credits for their research, would have to reconsider (i.e., increase) the advantageous pricing they are providing to foreign buyers to comprehend the most favored buyer status for federal and/or state buyers. Foreign buyers don’t seem to worry as much about U.S. patents – see India).
Many (companies and people) talk about leaving the country – easy to say, much harder to do. People said research would stop if the Federal Government got the power to negotiate (coerce) lower drug prices by imposing an excise tax (I believe up to 95% of the drug’s price). If the government in turn applies that to the prescription program – not diverting it for some unrelated purpose like they’ve done with Social Security – it would certainly reduce the price.
Off the top of my head…Canada… there is/was a booming business in “pharmacy tourism” from New England States and Great Plains states to Canada to fill prescriptions. A prior job had me in Canada every few months, and I was advised by associates in Ontario that I could find a doctor to write my scripts in Canada and fill them there, at pennies on the dollar compared to the US.
Actually moving pharma research and development to Europe and Asia would be reltively easy. Ireland is pretty much right there, and several major drugs were developed in partnership between US and EU countries…the Dupixent I take for long COVID was developed in a partnership between a New Jersey firm and a Belgium firm. Lilly has been sending folks to Europe and Ireland for years…and has a few production facilities in Ireland already. Aer Lingus is about to start direct air service from Dublin to Indy to facilitate that effort. Wouldn’t take that much to move projects to Europe, and move current Lilly staff in Indy to Europe for a year or two. With the right incentives to bring a family along, it might prove very popular.
Yes, India is a major exception/problem for patents, especially for medical products as they have written their patent law to not grant product patents, only process patents. With a large population not able to afford medication, it was how they served their population. I’m not defending it…but that is the reality. But India is an exception, not a the general rule. And its not just US patents, its all medical patents…EU, Asian, US.